Matthias Miller started to work as a clinical project manager for the BioNTech AG in August 2014. Here, he is involved in the management of the first-in-human clinical trial utilising poly-epitopic RNA-vaccines targeting mutation-derived neoantigens. The clinical development of this so-called IVAC®-approach and the implementation of novel technologies into the
process constitute his main area of work. Before he started his work at the BioNTech, he acquired his Ph.D. at the German Cancer Research Center (DKFZ) in Heidelberg, where he also performed postdoctoral work in the Innate Immunity research group. During his time at the DKFZ, he investigated adaptive features of innate immune cells in the context of tumour immunotherapies. Matthias Miller studied biochemistry at the
Eberhard Karls University in Tübingen and wrote his diploma thesis at the department of immunology focusing on the identification of T-cell epitopes from malignant melanoma.